| |  Online-Ressource |
|---|
| Verfasst von: | Rheinheimer, Stephan [VerfasserIn]  |
|---|
| | Heußel, Claus Peter [VerfasserIn] |
|---|
| | Mayer, Philipp [VerfasserIn] |
|---|
| | Bozorgmehr, Farastuk [VerfasserIn] |
|---|
| | Winter, Hauke [VerfasserIn] |
|---|
| | Herth, Felix [VerfasserIn] |
|---|
| | Muley, Thomas [VerfasserIn] |
|---|
| | Liersch, Stephan [VerfasserIn] |
|---|
| | Bischoff, Helge [VerfasserIn] |
|---|
| | Kriegsmann, Mark [VerfasserIn] |
|---|
| | El-Shafie, Rami [VerfasserIn] |
|---|
| | Stenzinger, Albrecht [VerfasserIn] |
|---|
| | Thomas, Michael [VerfasserIn] |
|---|
| | Kauczor, Hans-Ulrich [VerfasserIn] |
|---|
| | Christopoulos, Petros [VerfasserIn] |
|---|
| Titel: | Oligoprogressive non-small-cell lung cancer under treatment with PD-(L)1 inhibitors |
|---|
| Verf.angabe: | Stephan Rheinheimer, Claus-Peter Heussel, Philipp Mayer, Lena Gaissmaier, Farastuk Bozorgmehr, Hauke Winter, Felix J. Herth, Thomas Muley, Stephan Liersch, Helge Bischoff, Mark Kriegsmann, Rami A. El Shafie, Albrecht Stenzinger, Michael Thomas, Hans-Ulrich Kauczor and Petros Christopoulos |
|---|
| E-Jahr: | 2020 |
|---|
| Jahr: | 23 April 2020 |
|---|
| Umfang: | 13 S. |
|---|
| Fussnoten: | Gesehen am 17.07.2020 |
|---|
| Titel Quelle: | Enthalten in: Cancers |
|---|
| Ort Quelle: | Basel : MDPI, 2009 |
|---|
| Jahr Quelle: | 2020 |
|---|
| Band/Heft Quelle: | 12(2020), 4, Artikel-ID 1046, Seite 1-13 |
|---|
| ISSN Quelle: | 2072-6694 |
|---|
| Abstract: | Oligoprogression (OPD) of non-small-cell lung cancer (NSCLC) occurs in approximately half of patients under targeted compounds (TKI) and facilitates use of regional therapies that can prolong survival. In order to characterize OPD in immunotherapy (IO)-treated NSCLC, we analyzed the failure pattern under PD-1/PD-L1 inhibitors (n = 297) or chemoimmunotherapy (n = 75). Under IO monotherapy, OPD was more frequent (20% vs. 10%, p < 0.05), occurred later (median 11 vs. 5 months, p < 0.01), affected fewer sites (mean 1.1 vs. 1.5, p < 0.05), and involved fewer lesions (1.4 vs. 2.3, p < 0.05) in the first compared to later lines. Lymph nodes (42%, mainly mediastinal) and the brain (39%) were mostly affected, followed by the lung (24%) and other organs. Compared to multifocal progression, OPD occurred later (11 vs. 4 months, p < 0.001) and was associated with longer survival (26 vs. 13 months, p < 0.001) and higher tumor PD-L1 expression (p < 0.001). Chemoimmunotherapy showed a similar incidence of OPD as IO monotherapy (13% vs. 11% at 2 years). Local treatments were applied regularly for brain but only in 50% for extracranial lesions. Thus, NSCLC oligoprogression is less common under IO than under TKI, but also favorable. Since its frequency drops later in the disease, regular restaging and multidisciplinary evaluation are essential in order to exploit the full therapeutic potential. |
|---|
| DOI: | doi:10.3390/cancers12041046 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.3390/cancers12041046 |
|---|
| | Volltext: https://www.mdpi.com/2072-6694/12/4/1046 |
|---|
| | DOI: https://doi.org/10.3390/cancers12041046 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | chemoimmunotherapy |
|---|
| | immunotherapy |
|---|
| | local therapy |
|---|
| | non-small-cell lung cancer |
|---|
| | oligoprogression |
|---|
| K10plus-PPN: | 172507432X |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Oligoprogressive non-small-cell lung cancer under treatment with PD-(L)1 inhibitors / Rheinheimer, Stephan [VerfasserIn]; 23 April 2020 (Online-Ressource)
